Clinical Trial Update: Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 2 neoadjuvant study combining zanidatamab, tislelizumab, and chemotherapy to enable selective bladder preservation …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Muscle-invasive Bladder Cancer

Drugs mentioned

• Chemotherapy (chemotherapy)
• Tislelizumab (tislelizumab)
• Zanidatamab

Snippet

Sponsor: Fujian Medical University Union Hospital | Conditions: Muscle Invasive Bladder Cancer (MIBC) | Phase 2 | Status: RECRUITING